Novartis gets US approval for $2.1 million gene therapy
Swiss pharmaceutical company Novartis has received US regulatory approval for a gene therapy that has a price tag of $2.1 million (AFP Photo/SEBASTIEN BOZON)/ Washington (AFP) - Swiss pharmaceutical company Novartis on Friday announced it had received US regulatory approval for a gene therapy that treats a rare childhood disorder and has a price tag of $2.1 million, making it the most expensive drug in history. The company said Zolgensma was a one-time treatment for spinal muscular atrophy, a disease that affects about 1 in 10,000 births ...
Click
To Read Full Article